Genetic variations frequencies in Wilms’ tumor: a meta-analysis and systematic review

Abstract

Over the last few decades, numerous biomarkers, have been confirmed and shown variations in the prevalence. Most of these studies were based on small sample sizes. We carried out a meta-analysis of the research published up to 15 September 2015 to obtain more precise and comprehensive outcome for genetic tests. In the present study, 70 studies out of 5175 papers were eligible for meta-analysis. Meta-analysis was done with Stata 12.0. Pooled prevalence for gene mutations (WT1, WTX, CTNNB1, TP53, MYCN, DROSHA and DGCR8) was 0.147 (0.109, 0.185), 0.149 (0.110, 0.186), 0.140 (0.100, 0.190), 0.474 (0.342, 0.606), 0.099 (0.063, 0.136), 0.096 (0.050, 0.141) and 0.037 (0.025, 0.049), respectively. Pooled prevalence of LOH at 1p, 11p, 11q, 16q, and 22q was 0.109 (0.084, 0.133), 0.334 (0.295, 0.373), 0.199 (0.146, 0.252), 0.151 (0.129, 0.172) and 0.148 (0.108, 0.189), respectively. Pooled prevalence of 1q and chromosome 12 gain was 0.218 (0.161, 0.275) and 0.273 (0.195, 0.350). The limited prevalence of currently known genetic alterations in Wilms' tumors indicates that significant drivers of initiation and progression remain to be discovered. Subgroup analyses indicate that the ethnicity maybe one of the sources of heterogeneity. However, in meta regression analyses, No study-level characteristics of indicators were found significant. In addition, Sensitivity analysis and the publication bias of some results hint us interpret those results with caution.

This article is protected by copyright. All rights reserved.

from Cancer via ola Kala on Inoreader http://ift.tt/1VrsfCP
via IFTTT